top of page

About us

Our aim is to develop the most rigid and experimentally backed protocols for regenerative therapies. Continually assessing best practice and developing our own in-house research procedures, we aim to provide you with the most effective treatments possible. Many treatments available and widely accepted have been proven clinically, but lack rigid protocols for different therapy preparation and delivery methods. Our processes are always based upon quality, scientifically sound research publications. 

 

Science can be inaccessible and expensive, which we believe slows some of the greatest innovation. As a new research entity, we aim to fund our research by providing you with established treatments that help us meet funding requirements. We are creating a self circulating research-funding process. 

By offering you aesthetic and functional therapies, we are able to remove ourselves from a very hostile funding circuit. As our research is currently small scale, not requiring large, expensive lab equipment, we can focus on delivering exceptional quality in our treatments and in our research endeavours. 

PreGen is a small venture designed to build on a design developed by our founder, who masters in Nanotechnology & Regenerative medicine. This design is a biomimetic bicuspid valve with a tricuspid valve in development. The end goal is to see this treatment available for implant in the millions of people who suffer from incompetent valves. The aim is to create a treatment that doesn't require the patient to spend a life on immunosuppressant drugs and a device lasts the lifespan of the patient without intervention. This is of course a very lengthy process with many variables to consider to ensure absolute safety in its application. With a process potentially spanning 5+ years before human application, funding and time are the two biggest assets to this treatment, thus PreGen being developed to meet the needs of our planned ree

Literature

1. What is Regenerative medicine?  (Click to read more)

2. Jakfar S, Lin TC, Wu SC, Wang YH, Sun YJ, Thacker M, Liu LX, Lin FH. New design to remove leukocytes from platelet-rich plasma (PRP) based on cell dimension rather than density. Bioact Mater. 2021 Mar 22;6(10):3528-3540. doi: 10.1016/j.bioactmat.2021.03.002. PMID: 33842739; PMCID: PMC8008179.

3. Draelos, ZD, Rheins, LA, Wootten, S, Kellar, RS, Diller, R. Pilot study: Autologous platelet-rich plasma used in a topical cream for facial rejuvenation. J Cosmet Dermatol. 2019; 18: 1348–1352. https://doi.org/10.1111/jocd.13088

 

4. Anuj Marathe, Shiv J. Patel, Bo Song, Joseph M. Sliepka, Theodore S. Shybut, Brendan H. Lee, Prathap Jayaram. Double-Spin Leukocyte-Rich Platelet-Rich Plasma Is Predominantly Lymphocyte Rich With Notable Concentrations of Other White Blood Cell Subtypes. Arthroscopy, Sports Medicine, and Rehabilitation, Volume 4, Issue 2, 2022, Pages e335-e341, https://doi.org/10.1016/j.asmr.2021.10.004.

 

5. Nitecka-Buchta Aleksandra, Walczynska-Dragon Karolina, Kempa Wojciech Michal, Baron Stefan. Platelet-Rich Plasma Intramuscular Injections — Antinociceptive Therapy in Myofascial Pain Within Masseter Muscles in Temporomandibular Disorders Patients: A Pilot Study Frontiers in Neurology. Vol,10. 2019. https://www.frontiersin.org/articles/10.3389/fneur.2019.00250. DOI:10.3389/fneur.2019.00250  

 

6. Harrison TE, Bowler J, Levins TN, Reeves KD, Cheng AL. Platelet-Rich Plasma Centrifugation Changes Leukocyte Ratios. Cureus. 2021 Apr 13;13(4):e14470. doi: 10.7759/cureus.14470. PMID: 33996329; PMCID: PMC8115186.

 

7. Mao AS, Mooney DJ. Regenerative medicine: Current therapies and future directions. Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):14452-9. doi: 10.1073/pnas.1508520112. PMID: 26598661; PMCID: PMC4664309.

8. Khunger N. Complications in Cosmetic Surgery: A Time to Reflect and Review and not Sweep Them Under the Carpet. J Cutan Aesthet Surg. 2015 Oct-Dec;8(4):189-90. doi: 10.4103/0974-2077.172188. PMID: 26865782; PMCID: PMC4728899.

bottom of page